{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:17:42Z","timestamp":1792671462176,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DP1DK143574"],"award-info":[{"award-number":["DP1DK143574"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["R01EB027223"],"award-info":[{"award-number":["R01EB027223"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["R01EB030102"],"award-info":[{"award-number":["R01EB030102"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS128461"],"award-info":[{"award-number":["R01NS128461"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["UG3MH126861"],"award-info":[{"award-number":["UG3MH126861"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41434-025-00585-y","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:13:41Z","timestamp":1765210421000},"page":"486-494","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intranasal versus intravenous AAV delivery: A comparative analysis of brain-targeting efficiency and peripheral exposure in mice"],"prefix":"10.1038","volume":"33","author":[{"given":"Chinwendu","family":"Chukwu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyun","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1904-0857","authenticated-orcid":false,"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"585_CR1","doi-asserted-by":"publisher","first-page":"220","DOI":"10.5603\/PJNNS.a2020.0046","volume":"54","author":"MS Fiandaca","year":"2020","unstructured":"Fiandaca MS, Lonser RR, Elder JB, Z\u0105bek M, Bankiewicz KS. Advancing gene therapies, methods, and technologies for Parkinson\u2019s Disease and other neurological disorders. Neurol Neurochir Pol. 2020;54:220\u201331.","journal-title":"Neurol Neurochir Pol"},{"key":"585_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/1061186X.2019.1630415","volume":"28","author":"SA Pena","year":"2020","unstructured":"Pena SA, Iyengar R, Eshraghi RS, Bencie N, Mittal J, Aljohani A, et al. Gene therapy for neurological disorders: challenges and recent advancements. J Drug Target. 2020;28:111\u201328.","journal-title":"J Drug Target"},{"key":"585_CR3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s12035-021-02555-y","volume":"59","author":"DGT Parambi","year":"2022","unstructured":"Parambi DGT, Alharbi KS, Kumar R, Harilal S, Batiha GES, Cruz-Martins N, et al. Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases. Mol Neurobiol. 2022;59:191\u2013233.","journal-title":"Mol Neurobiol"},{"key":"585_CR4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41583-024-00829-7","volume":"25","author":"J Gao","year":"2024","unstructured":"Gao J, Gunasekar S, Xia Z, Shalin K, Jiang C, Chen H, et al. Gene therapy for CNS disorders: modalities, delivery and translational challenges. Nat Rev Neurosci. 2024;25:553\u201372.","journal-title":"Nat Rev Neurosci"},{"key":"585_CR5","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1016\/j.ymthe.2022.09.015","volume":"30","author":"A Pupo","year":"2022","unstructured":"Pupo A, Fern\u00e1ndez A, Low SH, Fran\u00e7ois A, Su\u00e1rez-Amar\u00e1n L, Samulski RJ. AAV vectors: The Rubik\u2019s cube of human gene therapy. Mol Ther. 2022;30:3515\u201341.","journal-title":"Mol Ther"},{"key":"585_CR6","doi-asserted-by":"publisher","first-page":"809118","DOI":"10.3389\/fmed.2021.809118","volume":"8","author":"HKE Au","year":"2022","unstructured":"Au HKE, Isalan M, Mielcarek M. Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings. Front Med. 2022;8:809118.","journal-title":"Front Med"},{"key":"585_CR7","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41573-023-00766-7","volume":"22","author":"Q Ling","year":"2023","unstructured":"Ling Q, Herstine JA, Bradbury A, Gray SJ. AAV-based in vivo gene therapy for neurological disorders. Nat Rev Drug Discov. 2023;22:789\u2013806.","journal-title":"Nat Rev Drug Discov"},{"key":"585_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41434-023-00417-x","volume":"31","author":"M Singh","year":"2024","unstructured":"Singh M, Brooks A, Toofan P, McLuckie K. Selection of appropriate non-clinical animal models to ensure translatability of novel AAV-gene therapies to the clinic. Gene Ther. 2024;31:56\u201363.","journal-title":"Gene Ther"},{"key":"585_CR9","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1177\/1060028020914274","volume":"54","author":"D Stevens","year":"2020","unstructured":"Stevens D, Claborn MK, Gildon BL, Kessler TL, Walker C. Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy. Ann Pharmacother. 2020;54:1001\u20139.","journal-title":"Ann Pharmacother"},{"key":"585_CR10","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jconrel.2023.01.067","volume":"355","author":"L Kang","year":"2023","unstructured":"Kang L, Jin S, Wang J, Lv Z, Xin C, Tan C, et al. AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges. J Controlled Release. 2023;355:458\u201373.","journal-title":"J Controlled Release"},{"key":"585_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","volume":"8","author":"D Wu","year":"2023","unstructured":"Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood\u2013brain barrier: structure, regulation, and drug delivery. Signal Transduct Target Ther. 2023;8:217.","journal-title":"Signal Transduct Target Ther"},{"key":"585_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/toxsci\/kfw072","volume":"152","author":"BR Vuillemenot","year":"2016","unstructured":"Vuillemenot BR, Korte S, Wright TL, Adams EL, Boyd RB, Butt MT. Safety evaluation of CNS administered biologics-study design, data interpretation, and translation to the clinic. Toxicol Sci. 2016;152:3\u20139.","journal-title":"Toxicol Sci"},{"key":"585_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/978-1-4939-9139-6_8","volume":"1950","author":"DJ Gessler","year":"2019","unstructured":"Gessler DJ, Tai PWL, Li J, Gao G. Intravenous infusion of AAV for widespread gene delivery to the nervous system. Methods Mol Biol. 2019;1950:143\u201363.","journal-title":"Methods Mol Biol"},{"key":"585_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1001263","volume":"13","author":"W Shen","year":"2022","unstructured":"Shen W, Liu S, Ou L. rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis. Front Immunol. 2022;13:1001263.","journal-title":"Front Immunol"},{"key":"585_CR15","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","volume":"64","author":"JJ Lochhead","year":"2012","unstructured":"Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012;64:614\u201328.","journal-title":"Adv Drug Deliv Rev"},{"key":"585_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.nurt.2009.02.001","volume":"6","author":"MJ Kubek","year":"2009","unstructured":"Kubek MJ, Domb AJ, Veronesi MC. Attenuation of Kindled Seizures by Intranasal Delivery of Neuropeptide-Loaded Nanoparticles. Neurotherapeutics. 2009;6:359\u201371.","journal-title":"Neurotherapeutics"},{"key":"585_CR17","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1093\/ijnp\/pyaa054","volume":"23","author":"AA Math\u00e9","year":"2020","unstructured":"Math\u00e9 AA, Michaneck M, Berg E, Charney DS, Murrough JW. A randomized controlled trial of intranasal Neuropeptide Y in patients with major depressive disorder. Int J Neuropsychopharmacol. 2020;23:783\u201390.","journal-title":"Int J Neuropsychopharmacol"},{"key":"585_CR18","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1002\/jps.21939","volume":"99","author":"MM Migliore","year":"2010","unstructured":"Migliore MM, Vyas TK, Campbell RB, Amiji MM, Waszczak BL. Brain delivery of proteins by the intranasal route of administration: A comparison of cationic liposomes versus aqueous solution formulations. J Pharm Sci. 2010;99:1745\u201361.","journal-title":"J Pharm Sci"},{"key":"585_CR19","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1208\/s12248-015-9719-7","volume":"17","author":"ME Meredith","year":"2015","unstructured":"Meredith ME, Salameh TS, Banks WA. Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases. AAPS J. 2015;17:780\u20137.","journal-title":"AAPS J"},{"key":"585_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ijpharm.2007.03.039","volume":"340","author":"X Gao","year":"2007","unstructured":"Gao X, Chen J, Tao W, Zhu J, Zhang Q, Chen H, et al. UEA I-bearing nanoparticles for brain delivery following intranasal administration. Int J Pharm. 2007;340:207\u201315.","journal-title":"Int J Pharm"},{"key":"585_CR21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ijpharm.2013.11.049","volume":"461","author":"C Zhang","year":"2014","unstructured":"Zhang C, Chen J, Feng C, Shao X, Liu Q, Zhang Q, et al. Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer\u2019s disease. Int J Pharm. 2014;461:192\u2013202.","journal-title":"Int J Pharm"},{"key":"585_CR22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ymgme.2012.02.006","volume":"106","author":"DA Wolf","year":"2012","unstructured":"Wolf DA, Hanson LR, Aronovich EL, Nan Z, Low WC, Frey WH, et al. Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration. Mol Genet Metab. 2012;106:131\u20134.","journal-title":"Mol Genet Metab"},{"key":"585_CR23","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1089\/hum.2017.187","volume":"28","author":"LR Belur","year":"2017","unstructured":"Belur LR, Temme A, Podetz-Pedersen KM, Riedl M, Vulchanova L, Robinson N, et al. Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type i. Hum Gene Ther. 2017;28:576\u201387.","journal-title":"Hum Gene Ther"},{"key":"585_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2021.618360","volume":"14","author":"LR Belur","year":"2021","unstructured":"Belur LR, Romero M, Lee J, Podetz-Pedersen KM, Nan Z, Riedl MS, et al. Comparative Effectiveness of Intracerebroventricular, Intrathecal, and Intranasal Routes of AAV9 Vector Administration for Genetic Therapy of Neurologic Disease in Murine Mucopolysaccharidosis Type I. Front Mol Neurosci. 2021;14:618360.","journal-title":"Front Mol Neurosci"},{"key":"585_CR25","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s11064-016-1841-0","volume":"41","author":"XC Ma","year":"2016","unstructured":"Ma XC, Chu Z, Zhang XL, Jiang WH, Jia M, Dang YH, et al. Intranasal Delivery of Recombinant NT4-NAP\/AAV Exerts Potential Antidepressant Effect. Neurochem Res. 2016;41:1375\u201380.","journal-title":"Neurochem Res"},{"key":"585_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/srep22404","volume":"6","author":"XC Ma","year":"2016","unstructured":"Ma XC, Liu P, Zhang XL, Jiang WH, Jia M, Wang CX, et al. Intranasal Delivery of Recombinant AAV Containing BDNF Fused with HA2TAT: A Potential promising therapy strategy for major depressive disorder. Sci Rep. 2016;6:22404.","journal-title":"Sci Rep"},{"key":"585_CR27","doi-asserted-by":"publisher","first-page":"10103","DOI":"10.18632\/oncotarget.14356","volume":"8","author":"F Liu","year":"2017","unstructured":"Liu F, Liu YP, Lei G, Liu P, Chu Z, Gao CG, et al. Antidepressant effect of recombinant NT4-NAP\/AAV on social isolated mice through intranasal route. Oncotarget. 2017;8:10103\u201313.","journal-title":"Oncotarget"},{"key":"585_CR28","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2147\/NDT.S369412","volume":"18","author":"XL Li","year":"2022","unstructured":"Li XL, Liu H, Liu SH, Cheng Y, Xie GJ. Intranasal Administration of Brain-Derived Neurotrophic Factor Rescues Depressive-Like Phenotypes in Chronic Unpredictable Mild Stress Mice. Neuropsychiatr Dis Treat. 2022;18:1885\u201394.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"585_CR29","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2147\/NDT.S227598","volume":"16","author":"C Chen","year":"2020","unstructured":"Chen C, Dong Y, Liu F, Gao C, Ji C, Dang Y, et al. A study of antidepressant effect and mechanism on intranasal delivery of BDNF-HA2TAT\/AAV to rats with post-stroke depression. Neuropsychiatr Dis Treat. 2020;16:637\u201349.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"585_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-020-00596-3","volume":"13","author":"B Qi","year":"2020","unstructured":"Qi B, Yang Y, Cheng Y, Sun D, Wang X, Khanna R, et al. Nasal delivery of a CRMP2-derived CBD3 adenovirus improves cognitive function and pathology in APP\/PS1 transgenic mice. Mol Brain. 2020;13:58.","journal-title":"Mol Brain"},{"key":"585_CR31","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.nbd.2003.07.005","volume":"14","author":"J Zhang","year":"2003","unstructured":"Zhang J, Wu X, Qin C, Qi J, Ma S, Zhang H, et al. A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and \u03b2-amyloid plaques in a mouse model of Alzheimer\u2019s disease. Neurobiol Dis. 2003;14:365\u201379.","journal-title":"Neurobiol Dis"},{"key":"585_CR32","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1182\/blood-2002-09-2889","volume":"102","author":"AM Davidoff","year":"2003","unstructured":"Davidoff AM, Ng CYC, Zhou J, Spence Y, Nathwani AC. Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood. 2003;102:480.","journal-title":"Blood"},{"key":"585_CR33","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1089\/hum.2007.072","volume":"18","author":"A Voutetakis","year":"2007","unstructured":"Voutetakis A, Zheng C, Wang J, Goldsmith CM, Afione S, Chiorini JA, et al. Gender differences in serotype 2 adeno-associated virus biodistribution after administration to rodent salivary glands. Hum Gene Ther. 2007;18:1109\u201318.","journal-title":"Hum Gene Ther"},{"key":"585_CR34","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/gt.2011.42","volume":"18","author":"C Pfeifer","year":"2011","unstructured":"Pfeifer C, Aneja MK, Hasenpusch G, Rudolph C. Adeno-associated virus serotype 9-mediated pulmonary transgene expression: Effect of mouse strain, animal gender and lung inflammation. Gene Ther. 2011;18:1034\u201342.","journal-title":"Gene Ther"},{"key":"585_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/ebm.2025.10422","volume":"250","author":"E Guzman","year":"2025","unstructured":"Guzman E, Khoo C, O\u2019Connor D, Devarajan G, Iqball S, Souberbielle B, et al. Gender difference in pre-clinical liver-directed gene therapy with lentiviral vectors. Exp Biol Med. 2025;250:10422.","journal-title":"Exp Biol Med"},{"key":"585_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-4-410","volume":"4","author":"AS Stephens","year":"2011","unstructured":"Stephens AS, Stephens SR, Morrison NA. Internal control genes for quantitative RT-PCR expression analysis in mouse osteoblasts, osteoclasts and macrophages. BMC Res Notes. 2011;4:410.","journal-title":"BMC Res Notes"},{"key":"585_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.975803","volume":"13","author":"HCJ Ertl","year":"2022","unstructured":"Ertl HCJ. Immunogenicity and toxicity of AAV gene therapy. Front Immunol. 2022;13:975803.","journal-title":"Front Immunol"},{"key":"585_CR38","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s11901-023-00624-5","volume":"22","author":"B Jagadisan","year":"2023","unstructured":"Jagadisan B, Dhawan A. Hepatotoxicity in Adeno-Associated Viral Vector Gene Therapy. Curr Hepatol Rep. 2023;22:276\u201390.","journal-title":"Curr Hepatol Rep"},{"key":"585_CR39","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.omtm.2020.10.011","volume":"19","author":"SN Mathiesen","year":"2020","unstructured":"Mathiesen SN, Lock JL, Schoderboeck L, Abraham WC, Hughes SM. CNS Transduction Benefits of AAV-PHP.eB over AAV9 Are Dependent on Administration Route and Mouse Strain. Mol Ther Methods Clin Dev. 2020;19:447\u201358.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"585_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104277","volume":"84","author":"D Ye","year":"2022","unstructured":"Ye D, Yuan J, Yang Y, Yue Y, Hu Z, Fadera S, et al. Incisionless targeted adeno-associated viral vector delivery to the brain by focused ultrasound-mediated intranasal administration. EBioMedicine. 2022;84:104277.","journal-title":"EBioMedicine"},{"key":"585_CR41","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI0215780","volume":"110","author":"A Auricchio","year":"2002","unstructured":"Auricchio A, O\u2019Connor E, Weiner D, Gao GP, Hildinger M, Wang L, et al. Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. J Clin Investig. 2002;110:499\u2013504.","journal-title":"J Clin Investig"},{"key":"585_CR42","doi-asserted-by":"publisher","first-page":"12993","DOI":"10.1073\/pnas.0601433103","volume":"103","author":"MP Limberis","year":"2006","unstructured":"Limberis MP, Wilson JM. Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered. Proc Natl Acad Sci USA. 2006;103:12993\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"585_CR43","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/mt.2011.146","volume":"19","author":"K Quinn","year":"2011","unstructured":"Quinn K, Quirion MR, Lo CY, Misplon JA, Epstein SL, Chiorini JA. Intranasal administration of adeno-associated virus type 12 (AAV12) leads to transduction of the nasal epithelia and can initiate transgene-specific immune response. Mol Ther. 2011;19:1990\u20138.","journal-title":"Mol Ther"},{"key":"585_CR44","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1089\/hum.2014.002","volume":"25","author":"M Myint","year":"2014","unstructured":"Myint M, Limberis MP, Bell P, Somanathan S, Haczku A, Wilson JM, et al. In vivo evaluation of adeno-associated virus gene transfer in airways of mice with acute or chronic respiratory infection. Hum Gene Ther. 2014;25:966\u201376.","journal-title":"Hum Gene Ther"},{"key":"585_CR45","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/mt.2008.261","volume":"17","author":"MP Limberis","year":"2009","unstructured":"Limberis MP, Vandenberghe LH, Zhang L, Pickles RJ, Wilson JM. Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro. Mol Ther. 2009;17:294\u2013301.","journal-title":"Mol Ther"},{"key":"585_CR46","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","volume":"14","author":"Z Wu","year":"2006","unstructured":"Wu Z, Asokan A, Samulski RJ. Adeno-associated Virus Serotypes: Vector Toolkit for Human Gene Therapy. Mol Ther. 2006;14:316\u201327.","journal-title":"Mol Ther"},{"key":"585_CR47","doi-asserted-by":"publisher","first-page":"e76310","DOI":"10.1371\/journal.pone.0076310","volume":"8","author":"DF Aschauer","year":"2013","unstructured":"Aschauer DF, Kreuz S, Rumpel S. Analysis of Transduction Efficiency, Tropism and Axonal Transport of AAV Serotypes 1, 2, 5, 6, 8 and 9 in the Mouse Brain. PLoS ONE. 2013;8:e76310.","journal-title":"PLoS ONE"},{"key":"585_CR48","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3390\/cells12050785","volume":"12","author":"SS Issa","year":"2023","unstructured":"Issa SS, Shaimardanova AA, Solovyeva VV, Rizvanov AA. Various AAV Serotypes and their applications in gene therapy: an overview. Cells. 2023;12:785.","journal-title":"Cells"},{"key":"585_CR49","doi-asserted-by":"publisher","first-page":"e10611","DOI":"10.1371\/journal.pone.0010611","volume":"5","author":"JY Qin","year":"2010","unstructured":"Qin JY, Zhang L, Clift KL, Hulur I, Xiang AP, Ren BZ, et al. Systematic comparison of constitutive promoters and the doxycycline-inducible promoter. PLoS ONE. 2010;5:e10611.","journal-title":"PLoS ONE"},{"key":"585_CR50","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1089\/hum.2020.196","volume":"31","author":"MO Bohlen","year":"2020","unstructured":"Bohlen MO, McCown TJ, Powell SK, El-Nahal HG, Daw T, Basso MA, et al. Adeno-associated virus capsid-promoter interactions in the brain translate from rat to the nonhuman primate. Hum Gene Ther. 2020;31:1155\u201368.","journal-title":"Hum Gene Ther"},{"key":"585_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.685802","volume":"12","author":"DJ Finneran","year":"2021","unstructured":"Finneran DJ, Njoku IP, Flores-Pazarin D, Ranabothu MR, Nash KR, Morgan D, et al. Toward Development of Neuron Specific Transduction After Systemic Delivery of Viral Vectors. Front Neurol. 2021;12:685802.","journal-title":"Front Neurol"},{"key":"585_CR52","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.3390\/biomedicines11102725","volume":"11","author":"L Li","year":"2023","unstructured":"Li L, Vasan L, Kartono B, Clifford K, Attarpour A, Sharma R, et al. Advances in Recombinant Adeno-Associated Virus Vectors for Neurodegenerative Diseases. Biomedicines. 2023;11:2725.","journal-title":"Biomedicines"},{"key":"585_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202004018","volume":"8","author":"HJ Wagner","year":"2021","unstructured":"Wagner HJ, Weber W, Fussenegger M. Synthetic Biology: Emerging Concepts to Design and Advance Adeno-Associated Viral Vectors for Gene Therapy. Adv Sci. 2021;8:2004018.","journal-title":"Adv Sci"},{"key":"585_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1607","volume":"14","author":"VV Kolesnik","year":"2024","unstructured":"Kolesnik VV, Nurtdinov RF, Oloruntimehin ES, Karabelsky AV, Malogolovkin AS. Optimization strategies and advances in the research and development of AAV-based gene therapy to deliver large transgenes. Clin Transl Med. 2024;14:e1607.","journal-title":"Clin Transl Med"},{"key":"585_CR55","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40259-023-00585-7","volume":"37","author":"M Arjomandnejad","year":"2023","unstructured":"Arjomandnejad M, Dasgupta I, Flotte TR, Keeler AM. Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer. BioDrugs. 2023;37:311\u201329.","journal-title":"BioDrugs"},{"key":"585_CR56","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.3390\/ijms24043390","volume":"24","author":"E Marcello","year":"2023","unstructured":"Marcello E, Chiono V. Biomaterials-Enhanced Intranasal Delivery of Drugs as a Direct Route for Brain Targeting. Int J Mol Sci. 2023;24:3390.","journal-title":"Int J Mol Sci"},{"key":"585_CR57","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/nn.4593","volume":"20","author":"KY Chan","year":"2017","unstructured":"Chan KY, Jang MJ, Yoo BB, Greenbaum A, Ravi N, Wu WL, et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat Neurosci. 2017;20:1172\u20139.","journal-title":"Nat Neurosci"},{"key":"585_CR58","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jconrel.2021.03.029","volume":"333","author":"W Chen","year":"2021","unstructured":"Chen W, Yao S, Wan J, Tian Y, Huang L, Wang S, et al. BBB-crossing adeno-associated virus vector: An excellent gene delivery tool for CNS disease treatment. J Controlled Release. 2021;333:129\u201338.","journal-title":"J Controlled Release"},{"key":"585_CR59","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.medj.2022.11.002","volume":"4","author":"AC Stanton","year":"2023","unstructured":"Stanton AC, Lagerborg KA, Tellez L, Krunnfusz A, King EM, Ye S, et al. Systemic administration of novel engineered AAV capsids facilitates enhanced transgene expression in the macaque CNS. Med. 2023;4:31\u201350.e8.","journal-title":"Med"},{"key":"585_CR60","doi-asserted-by":"publisher","first-page":"e3002112","DOI":"10.1371\/journal.pbio.3002112","volume":"21","author":"Q Huang","year":"2023","unstructured":"Huang Q, Chen AT, Chan KY, Sorensen H, Barry AJ, Azari B, et al. Targeting AAV vectors to the central nervous system by engineering capsid\u2013receptor interactions that enable crossing of the blood\u2013brain barrier. PLoS Biol. 2023;21:e3002112.","journal-title":"PLoS Biol"},{"key":"585_CR61","first-page":"439","volume":"10","author":"JT Trevino","year":"2020","unstructured":"Trevino JT, Quispe RC, Khan F, Novak V. Non-Invasive Strategies for Nose-to-Brain Drug Delivery. J Clin Trials. 2020;10:439.","journal-title":"J Clin Trials"},{"key":"585_CR62","doi-asserted-by":"publisher","first-page":"201","DOI":"10.4103\/0973-8398.45032","volume":"2","author":"S Bhise","year":"2008","unstructured":"Bhise S, Yadav A, Avachat A, Malayandi R. Bioavailability of intranasal drug delivery system. Asian J Pharm. 2008;2:201\u201315.","journal-title":"Asian J Pharm"},{"key":"585_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0928-0987(00)00087-7","volume":"11","author":"L Illum","year":"2000","unstructured":"Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci. 2000;11:1\u201318.","journal-title":"Eur J Pharm Sci"},{"key":"585_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.mex.2021.101266","volume":"8","author":"D Ye","year":"2021","unstructured":"Ye D, Chen H. Focused ultrasound-mediated intranasal brain drug delivery technique (FUSIN). MethodsX. 2021;8:101266.","journal-title":"MethodsX"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00585-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00585-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00585-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T09:02:08Z","timestamp":1786611728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00585-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["585"],"URL":"https:\/\/doi.org\/10.1038\/s41434-025-00585-y","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All animal procedures were approved by the Institutional Animal Care and Use Committee of Washington University in St. Louis (Protocol NO. 24-0222) and conducted in compliance with the National Institute of Health (NIH) Guidelines for animal research.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}